Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.53 |
| ▸ | PDE4A | P27815 | 15/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7323520 | 0.86 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL8067615 | 0.86 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL1028306 | 0.83 | PDE4D (0.50) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL7149759 | 0.83 | PDE4D (0.54) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7147675 | 0.82 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3976102 | 0.82 | PDE4B (0.57) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL7355462 | 0.81 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL13317191 | 0.81 | RECQL (0.61) | PDE4BPDE4APDE4CPDE4DRECQL | |
| SCHEMBL77974 | 0.81 | CA2 (0.61) | — | |
| SCHEMBL2958828 | 0.81 | RECQL (0.60) | PDE4BPDE4APDE4CPDE4DRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1238967-B1 | A process for the preparation of 1-(cyano(aryl)methyl) cyclohexanol | COUNCIL SCIENT IND RES (IN) | 2005-04-27 | — | — | EP | claimed |
| US-7649095-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| EP-1308440-B1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080287522-A1 | reduced or no emetogenic effects ; benzylated phosphodiesterase 4 inhibitors; e.g. Rolipram, Ariflo, Arofylline; preparation by benzylation using benzyl bromide or a derivative; antiinflammatory agents; to treat autoimmune diseases; cystic fibrosis | BIOLIPOX AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1524268-B1 | Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids | SMITHKLINE BEECHAM CORP (US) | 2007-01-17 | — | — | EP | disclosed |
| US-7109342-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-08-24 | — | — | US | disclosed |
| EP-1279662-B1 | Process for preparing phenylcyclohexan-1-ylcarboxylic acids | SMITHKLINE BEECHAM CORP (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1295869-B1 | Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids | SMITHKLINE BEECHAM CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1524268-A1 | Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids | SmithKline Beecham Corporation (US) | 2005-04-20 | — | — | EP | disclosed |
| CN-1094710-A | New cyclohexane derivant | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
| CN-1094711-A | New hexanaphthene ylidene derivatives | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
| CN-1094031-A | New hexanaphthene ylidene derivatives | SMITHKLINE BEECHAM CORP (US) | 1994-10-26 | — | — | CN | disclosed |
| CN-1092407-A | New cyclohexane ylidene derivatives | SMITHKLINE BEECHAM CORP (US) | 1994-09-21 | — | — | CN | disclosed |
| WO-1993019750-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993019751-A1 | COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993019747-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993019748-A1 | COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND FOR INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287522-A1 | reduced or no emetogenic effects ; benzylated phosphodiesterase 4 inhibitors; e.g. Rolipram, Ariflo, Arofylline; preparation by benzylation using benzyl bromide or a derivative; antiinflammatory agents; to treat autoimmune diseases; cystic fibrosis | PDE4B, PDE4A, PDE7A | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.